US-based Moderna will begin the final-stage clinical trial of its vaccine for the novel coronavirus that causes Covid-19 by July
The final study will include 30,000 people and its primary goal will be to show the vaccine prevents people from developing coronavirus symptoms.
The aim of the study will be to show definitive clinical proof that Moderna’s vaccine actually does prevent people from developing Covid-19, and, secondarily, that it prevents at least severe symptoms and cases that require hospitalization from materializing.
The company says it will administer 100 microgram dose of the experimental vaccine for maximum immune response and minimum adverse effects in the Phase-3 trial.
Moderna’s vaccine provides instructions to healthy cells to produce antibodies against the coronavirus.
